Merozolyn0.5 mg

Merozolyn is a thiazide-like diuretic used in the following settings:

Established / FDA-approved uses

• Hypertension: Merozolyn is indicated alone or in combination with other antihypertensive agents for the management of essential hypertension.
• Edema: Merozolyn is indicated for the treatment of salt and water retention (edema) associated with congestive heart failure, and edema associated with renal disease, including the nephrotic syndrome.

Guideline-supported / adjunct (combination therapy) uses

• Diuretic-resistant edema: Merozolyn is frequently combined with a loop diuretic (e.g., furosemide) under specialist supervision to achieve sequential nephron blockade in patients with diuretic resistance, such as those with advanced heart failure or chronic kidney disease. This combination produces a potent synergistic diuretic effect and requires close monitoring.

Merozolyn should only be used for indications and durations established by a qualified physician.

Each tablet of Metolazone generally contains Metolazone as the active ingredient, commonly available in strengths of 2.5 mg, 5 mg, and 10 mg, along with standard pharmaceutical excipients. Exact composition may vary by manufacturer/brand; refer to the specific product label.

Merozolyn is a quinazoline-derivative, sulfonamide-based diuretic that is pharmacologically classified as "thiazide-like" because it shares a similar mechanism of action with thiazide diuretics, despite a distinct chemical structure. A notable feature of Merozolyn is that, unlike classic thiazides, it retains diuretic efficacy even in patients with reduced kidney function, which makes it particularly useful in combination with loop diuretics for treating resistant fluid overload.

Merozolyn belongs to the therapeutic class of diuretics, specifically the thiazide-like (quinazoline) diuretics.

Metolazone acts primarily on the cortical diluting segment of the distal convoluted tubule (and to a lesser extent the proximal convoluted tubule) of the nephron, where it inhibits the sodium-chloride (Na+/Cl-) symporter, reducing reabsorption of sodium and chloride. This promotes excretion of sodium, chloride, and water, along with increased excretion of potassium and magnesium, producing a diuretic and antihypertensive effect. Unlike conventional thiazide diuretics, Metolazone remains effective even in patients with significantly reduced glomerular filtration rate, which underlies its clinical utility in renal impairment and in combination with loop diuretics for resistant edema.

Pharmacokinetics

• Onset: approximately 1 hour
• Peak effect: 2-8 hours
• Duration of action: approximately 12-24 hours
• Elimination: primarily renal, partly hepatic

Merozolyn is administered orally, usually as a tablet, with or without food.

• Take Merozolyn at the same time each day, preferably in the morning, to reduce the likelihood of nighttime urination disrupting sleep.
• Swallow the tablet whole with a glass of water; do not crush or chew unless directed by a physician.
• When used in combination with a loop diuretic for resistant edema, Merozolyn is often given a short time before the loop diuretic dose, as instructed by the physician.
• Do not stop or change the dose of Merozolyn without consulting a physician, as abrupt changes can cause fluid/electrolyte imbalance.

Merozolyn has several clinically significant drug interactions:

• Lithium: Merozolyn reduces renal clearance of lithium, increasing the risk of lithium toxicity; concurrent use should be avoided or lithium levels monitored closely.
• Loop diuretics (e.g., furosemide): Co-administration with Merozolyn produces a potent synergistic diuretic effect, useful therapeutically but carrying a substantial risk of profound diuresis, dehydration, and electrolyte depletion; requires close monitoring, especially at initiation.
• NSAIDs: May reduce the diuretic and antihypertensive effect of Merozolyn and increase risk of renal impairment when combined.
• Digoxin: Merozolyn-induced hypokalemia increases the risk of digoxin toxicity, including cardiac arrhythmias.
• Antidiabetic medications (insulin, oral hypoglycemics): Merozolyn can raise blood glucose, potentially reducing the effectiveness of these medications; blood glucose monitoring may be needed.
• ACE inhibitors/ARBs and other antihypertensives: Additive blood-pressure-lowering effect; risk of significant hypotension, particularly with the first dose or with volume depletion.
• Corticosteroids/ACTH: May increase the risk of hypokalemia when combined with Merozolyn.
• Cholestyramine/colestipol: May reduce absorption of Merozolyn; separate dosing times.

Inform your physician of all medications, supplements, and herbal products before starting Merozolyn.

Common and important side effects associated with Merozolyn include:

• Dizziness, lightheadedness, or headache
• Hypotension (low blood pressure), especially with volume depletion
• Electrolyte disturbances: hypokalemia, hyponatremia, hypomagnesemia, hypochloremic alkalosis
• Hyperuricemia (may precipitate gout attacks)
• Hyperglycemia
• Muscle cramps or weakness
• Gastrointestinal upset (nausea, vomiting, abdominal discomfort)
• Skin rash or photosensitivity (uncommon)
• Blood dyscrasias (rare)

Seek prompt medical attention for signs of severe electrolyte imbalance (e.g., muscle cramps, severe weakness, irregular heartbeat, confusion) while taking Merozolyn.

Pregnancy: Merozolyn should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Diuretics like Merozolyn do not prevent and may worsen pre-eclampsia, and are generally not recommended for routine treatment of dependent edema in otherwise healthy pregnant women. Always consult a physician before using Merozolyn during pregnancy.

Lactation: Merozolyn is excreted in small amounts in breast milk. Because diuretics may suppress lactation and effects on the nursing infant are not fully established, Merozolyn should be used during breastfeeding only under medical supervision, weighing benefits against potential risk.

Use Merozolyn with caution and under regular medical supervision:

• Electrolyte disturbances: Merozolyn can cause significant hypokalemia, hyponatremia, hypomagnesemia, and hypochloremic alkalosis, particularly when combined with loop diuretics; close electrolyte monitoring is essential, especially at the start of combination diuretic therapy.
• Volume depletion/hypotension: Especially with combination diuretic use, aggressive diuresis can cause significant volume depletion and symptomatic hypotension.
• Hyperuricemia/gout: Merozolyn may raise uric acid levels and precipitate gout attacks in susceptible individuals.
• Hyperglycemia: Blood glucose should be monitored, particularly in patients with diabetes or prediabetes.
• Renal function: Although Merozolyn can be used at more advanced degrees of renal impairment than many other thiazide-type diuretics, renal function should be monitored carefully during treatment, particularly with combination therapy.
• Lithium therapy: Concurrent use increases risk of lithium toxicity due to reduced renal clearance (see Interactions).
• Hepatic impairment: Use with caution, as electrolyte imbalance can precipitate hepatic encephalopathy; contraindicated in hepatic coma/precoma.
• Sulfonamide sensitivity: Use caution in patients with known sulfonamide allergy (see Contraindications).

Combination of Merozolyn with loop diuretics for resistant edema should only be undertaken under specialist supervision due to the potent synergistic diuretic effect and associated risks.

Overdose of Merozolyn may cause excessive diuresis leading to dehydration, electrolyte depletion (hypokalemia, hyponatremia), hypotension, lethargy, and in severe cases, circulatory collapse or coma. If overdose is suspected, seek immediate medical attention or contact a poison control center right away. Treatment is generally supportive, focusing on fluid and electrolyte correction under medical supervision; do not attempt to manage a suspected Merozolyn overdose at home.

Store Merozolyn at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Safety and effectiveness of Merozolyn in children have not been well established; use only if clearly needed and under close specialist supervision.

Elderly: Older adults may be more sensitive to the electrolyte-depleting and hypotensive effects of Merozolyn; a lower starting dose and close monitoring are advised.

Renal impairment: Merozolyn retains efficacy even in significant renal impairment, but should be used with careful monitoring (see Precautions and Warnings).

Hepatic impairment: Use with caution; contraindicated in hepatic coma/precoma (see Contraindications).

The duration of treatment with Merozolyn is individualized by the prescribing physician based on the indication (e.g., ongoing therapy for chronic hypertension or heart failure) and response to treatment. When used in combination with a loop diuretic for resistant edema, Merozolyn is often prescribed intermittently (e.g., a few times per week) rather than continuously, to reduce the risk of severe electrolyte disturbance. Treatment should be reviewed periodically, and Merozolyn should not be continued or discontinued without medical advice.

Metolazone is classified under: Diuretics > Thiazide-like diuretics (quinazoline-derivative, sulfonamide-type diuretic).

Metolazone inhibits sodium and chloride reabsorption at the cortical diluting segment of the distal renal tubule by blocking the Na+/Cl- symporter, increasing urinary excretion of sodium, chloride, and water, and secondarily increasing potassium and magnesium excretion. This natriuretic and diuretic action reduces plasma and extracellular fluid volume, lowering blood pressure and reducing edema.

B

The safety and effectiveness of Merozolyn in pediatric patients have not been well established. Merozolyn should be used in children only when clearly necessary, under close specialist supervision, with careful attention to fluid and electrolyte status.